Navigation Links
John Theurer Cancer Center presents significant blood cancer research at 2012 ASCO Annual Meeting
Date:5/29/2012

Hackensack, New Jersey (May 29, 2012) Physicians and researchers at John Theurer Cancer Center at HackensackUMC, one of the nation's top 50 cancer centers, will present the latest findings in blood-cancer research at the 2012 American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 1-5. Their involvement in these studies is part of John Theurer Cancer Center's continued focus to bolster its research program.

"We are proud to make a contribution to this premiere oncology conference, but we also know there is a lot of work ahead, " said Andre Goy, M.D., M.S., chairman and director and chief of lymphoma, John Theurer Cancer Center. "We are placing significant resources towards further advancing cancer research, such as the recent expansion of our Phase 1 Unit to spearhead early drug development."

Blood cancer research highlights include studies in multiple myeloma and leukemia, including two oral presentations evaluating combination therapies for multiple myeloma patients, results of a multicenter study for newly diagnosed chronic myeloma leukemia, findings of a multi-center phase II study evaluating dose regimens in older patients with MDS refractory, and an analysis of a salvage therapy for first relapse acute myeloid leukemia.

John Theurer Cancer Center oral and presentation highlights at the ASCO annual meeting include:

  • 6509 - Nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up, Stuart Goldberg, MD et all. Poster Session: June 1, 2012 1:00pm-5:00pm
  • 6520 - A randomized phase II study of sapacitabine in MDS refractory to hypomethylating agents, Stuart Goldberg, MD et. All. Poster Session: June 1, 2012 1:00-5:00pm
  • 6525 - Initial salvage therapy in first relapse AML: A phase IIb study of CPX-351 versus investigator's choiceA subset analysis by prognostic group, Stuart Goldberg, MD et all. Poster Session: June 1, 2012 1:00pm-5:00pm highlight this one more
  • 8011- Stringent complete response in patients with newly diagnosed multiple myeloma (NDMM) treated with carfilzomib, lenalidomide, and dexamethasone, David H. Vesole, MD, PhD et all. Oral Session: June 3, 2012 8:00am-11:00pm
  • 8016 - Pomalidomide with or without low-dose dexamethasone in patients with relapsed/refractory multiple myeloma: Outcomes in patients refractory to lenalidomide and/or bortezomib, David S. Siegel, MD, PhD et all. Oral Session: June 3, 2012 8:00am-11:00pm
  • 8035 - Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1, David S. Siegel, MD, PhD et all. Poster Session: June 2, 2012 8:00am-12:00pm
  • TPS6636 - A single-arm, open-label, multicenter study of complete molecular response in patients with newly diagnosed Philadelphia chromosomepositive chronic myeloid leukemia in chronic phase treated with nilotinib, Stuart Goldberg, MD et all. Poster Session: June 4, 2012 1:15pm-5:15pm

"Our research presented at this conference would not have been possible without the patients who participate in our clinical trials," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., chief innovation officer, professor and vice president of cancer services, John Theurer Cancer Center. "We are thankful to our patients, our researchers, and our partnering institutions who help us bring novel therapies and improved regimens for cancer patients."


'/>"/>

Contact: Amy Leahing
aleahing@p4strategy.com
John Theurer Cancer Center
Source:Eurekalert

Related biology news :

1. John Theurer Cancer Center BMT researchers highlight the importance of social support
2. John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting
3. National experts from the John Theurer Cancer Center will present 31 studies at the 2011 ASH Meeting
4. Breast cancer treatment resistance linked to signaling pathway
5. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
6. The dietary supplement genistein can undermine breast cancer treatment
7. Saliva proteins could help detection of oral cancer
8. Vitamin C supplements may reduce benefit from wide range of anti-cancer drugs
9. Breakthrough optical technology to assess colon cancer risk, accuracy
10. Breast cancer cells recycle to escape death by hormonal therapy
11. Nanodiamond drug device could transform cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
(Date:3/23/2016)... 23, 2016 ... Gesichts- und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler ... mit SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie ... die Möglichkeit angeboten, im Rahmen mobiler Apps ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... 2016 , ... Cancer experts from Austria, Hungary, Switzerland, and ... new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has just published ... , Biomarkers are components in the blood, tissue or body fluids that ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
Breaking Biology Technology: